Ezetimibe and vascular inflammation

Current Vascular Pharmacology

Volumn 9, Issue 1, 2011, Pages 99-108

  Ishibashi, Toshiyuki ^a,b   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Atherosclerosis; Cholesterol absorption; CRP; Ezetimibe; Inflammation; Statin

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN; SECRETORY PHOSPHOLIPASE A2; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ATHERECTOMY; BLOOD VESSEL WALL; CALCIUM SIGNALING; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID STORAGE; MULTICENTER STUDY; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; STROKE; T LYMPHOCYTE; TREATMENT RESPONSE; WESTERN BLOTTING;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERITIS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; META-ANALYSIS AS TOPIC;

EID: 78650963071     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111793744788     Document Type: Review

References (91)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-50.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-8.
5. Ross R. The pathogenesis of atherosclerosis. a perspective for the 1990s. Nature 1993; 362: 801-9.
6. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10: 63-71.
7. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
8. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Testing and clinical relevance. Circulation 2007; 115: 1285-95.
9. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005; 127: 2254-63.
10. Simons LA, von Konigsmark M, Simons J, Stocker R, Celermajer DS. Vitamin E ingestion does not improve arterial endothelial dys-function in older adults. Atherosclerosis 1999; 143: 193-9.
11. Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002; 89: 562-6.
12. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endo-thelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93.
13. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500.
14. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
15. Hahn C, Schwartz MA. The role of cellular adaptation to mechani-cal forces in atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 2101-7.
16. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum choles-terol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
17. Wassmann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-e103.
18. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
19. Kesäniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987; 17: 391-5.
20. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
21. Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
22. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 1999; 68: 459-86.
23. Perez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell. 2003; 112: 535-48.
24. Shinohara M, Terada Y, Iwamatsu A, et al. SWAP-70 is a guanine-nucleotide-exchange factor that mediates signaling of membrane ruffling. Nature 2002; 416: 759-63.
25. Yokoyama K, Ishibashi T, Ohkawara H, et al. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 2002; 105: 962-7.
26. Ohkawara H, Ishibashi T, Sakamoto T, et al. Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells. J Biol Chem 2005; 280: 10182-8.
27. Sugimoto K, Ishibashi T, Sawamura T, et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res 2009; 84: 127-36.
28. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 2004; 84: 869-901.
29. Eto M, Barandiér C, Rathgeb L, et al. Thrombin suppresses endo-thelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89: 583-90.
30. Wójciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 1999; 145: 1293-307.
31. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. Inducible expres-sion of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol 1993; 143: 1551-9.
32. Ishibashi T, Sakamoto T, Ohkawara H, et al. Integral role of RhoA activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 681-7.
33. 2+ influx through MCP-1 in endothelial cells by monocyte adhesion. Arterioscler Thromb Vasc Biol 2005; 25: 2005-11.
34. 2+ signaling. Atherosclerosis 2007; 193: 44-54.
35. Gómez-Garre D, Muñoz-Pacheco P, Gonzàlez-Rubio ML, Aragon-cillo P, Granados R, Fernàndez-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009; 156: 1218-27.
36. Kuhlencordt PJ, Padmapriya P, Rützel S, et al. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009; 202: 48-57.
37. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hy-droxymethylglutaryl coenzyme a reductase inhibitor, improves en-dothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-9.
38. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005; 97: 967-74.
39. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001; 107: 255-64.
40. Adams V, Linke A, Kränkel N, et al. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 2005; 111: 555-62.
41. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 2006; 71: 216-25.
42. 2+ signaling pathways in endothelial cells. J Cell Physiol 2009; 220: 706-15.
43. 2+ influx in tissue factor expression in monocyte adhesion to endothelial cells. J Atheroscler Thromb 2007; 14: 109-15.
44. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
45. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 1955-60.
46. Azumi H, Inoue N, Ohashi Y, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2002; 22: 1838-44.
47. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109: III2-7.
48. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109: III20-6.
49. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106: 2894-900.
50. Baldus S, Heeschen C, Meinertz T, et al.; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-5.
51. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279-86.
52. Ishibashi T, Kijima M, Yokoyama K, et al. Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease. Jpn Circ J 1999; 63: 249-54.
53. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-9. Erratum in: N Engl J Med 1997; 337-56.
54. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
55. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
56. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
57. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.
58. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003; 91: 287-92.
59. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007; 49: 2003-9.
60. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1380-9.
61. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
62. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-63.
63. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
64. Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultra-sound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002; 40: 220-7.
65. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-83.
66. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
67. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
68. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric in-travascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004; 110: 1061-8.
69. Hiro T, Kimura T, Morimoto T, et al.: JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin vs. atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293-302.
70. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-21.
71. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009; 203: 67-74.
72. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal by-pass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
73. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 2006; 48: 708-14.
74. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H; Finnish Treat-to-Target Study Investigators. Serum non-cholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003; 141: 131-7.
75. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. Brit Med J 1998; 317: 1252-53.
76. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-9.
77. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dosecomparison study of the combination of ezetimibe and simvastatin (Vytorin) vs. atorvastatin in patients with hypercholesterolemia: the Vytorin vs. Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73.
78. Galin ID, Smith DA. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) vs. atorvastatin in patients with hypercholesterolemia: the Vytorin vs. Atorvastatin (VYVA) Study. Am Heart J 2006; 151: e1.
79. Ballantyne CM, Weiss R, Moccetti T, et al.; EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-80.
80. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet vs. rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22: 2041-53.
81. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009; 119: 131-8.
82. Settergren M, Böhm F, Rydén L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008; 29: 1753-60.
83. Ostad MA, Eggeling S, Tschentscher P, et al. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009; 205: 227-32.
84. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852-8.
85. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009; 103: 369-74.
86. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-30.
87. Tzima E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ Res 2006; 98: 176-85.
88. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30.
89. Ohsuzu F. The roles of cytokines, inflammation and immunity in vascular diseases. J Atheroscler Thromb 2004; 11: 313-21.
90. Nagata K, Ishibashi T, Sakamoto T, et al. Rho/Rho-kinase is in-volved in the synthesis of tissue factor in human monocytes. Atherosclerosis 2002; 163: 39-47.
91. Ishibashi T, Nagata K, Ohkawara H, et al. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta 2002; 1590: 123-30.